Search clinical trials for: Wee-1 kinase inhibitor AZD1775

Total 11969 results

Children's Oncology Group
National Cancer Institute (NCI)

Recruiting

Stopping Tyrosine Kinase Inhibitors in Affecting Treatment-Free Remission in Patients With Chronic Phase Chronic Myeloid Leukemia

Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive

United States, Canada, Australia, Puerto Rico
The First Hospital of Jilin University

Recruiting

Lenvatinib Combined With PD-1 Inhibitors as First-line Treatment for Unresectable/Advanced Biliary Tract Carcinoma (LEADER-001)

Biliary Tract Cancer

China
AstraZeneca

Completed

Study of Cediranib Plus Cisplatin Plus Capecitabine/S-1 in Japanese Gastric Cancer Patients

Gastric Cancer

Japan
National Institutes of Health Clinical Center (CC)
CERN Foundation - Collaborative Ependymoma Research Network

Completed

Dose-Dense Temozolomide + Lapatinib for Recurrent Ependymoma

Brain Tumors | Spinal Cord Tumors

United States
Swiss Group for Clinical Cancer Research
Nordic Lymphoma Group

Terminated

Rituximab With or Without Ibrutinib for Patients With Advanced Follicular Lymphoma

Follicular Lymphoma

Sweden, Finland, Denmark, Norway, Switzerland, Austria
Guangzhou Medical University

Recruiting

Intra-pemetrexed Plus Third-generation Small Molecule TKI Drugs (e.g. 'Osimertinib') Versus Third-generation Small Molecule TKI Drugs Alone for Leptomeningeal Metastasis From Epidermal Growth Factor Receptor Mutation-Positive Non-Small-cell Lung Cancer

Leptomeningeal Metastasis

China
Integrative Skin Science and Research
AyurPrana LLC; Pearl Banyan, LLC

Not yet recruiting

The Effects of a Springtime Home Cleanse on Skin, Gut, Metabolic and Mental Health

Healthy

United States
University of Michigan
Blue Cross Blue Shield of Michigan Foundation

Completed

Tobacco Tactics Website for Operating Engineers (BCBSM-OE)

Smoking | Tobacco Use Cessation

United States
Chinese University of Hong Kong

Completed

Nasopharyngeal Carcinoma (NPC) Axitinib

Recurrent or Metastatic NPC

Hong Kong
Shinshu University

Recruiting

Examination of Efficacy and Safety of Baricitinib in RA Patients

Rheumatoid Arthritis

Japan
The Affiliated Nanjing Drum Tower Hospital of Nanjing...

Recruiting

Postoperative Adjuvant Therapy for Non-clear Renal Cell Carcinoma With High-risk Recurrence Factors (IUNU-RC)

Non-clear Renal Cell Carcinoma

China
Lutris Pharma Ltd.

Recruiting

LUT014 for the Reduction of Dose-Limiting Acneiform Lesions Associated With EGFRI Treatment of mCRC

EGFRI Induced Acneiform Lesions

United States, Israel
Shanghai Zhongshan Hospital

Unknown

SHR-1210 Plus Apatinib in Patients With Advanced-Stage Hepatocellular Carcinoma (SHR-1210)

Hepatocellular Carcinoma

China
GlaxoSmithKline

Completed

Study to Investigate Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of GSK2646264

Urticaria

Germany, United Kingdom
Shanghai Zhongshan Hospital

Unknown

SHR-1210 Plus Apatinib in Patients With Hepatocellular Carcinoma After Surgery

Hepatocellular Carcinoma

China
Chinese PLA General Hospital

Unknown

The Study of Conversion Surgery for Apatinib in Combination With SOX for Patients With Unresectable Gastric Cancer

Gastric Cancer

China
Dr. Sabrina Overhagen

Withdrawn

AndraTec PMCF Study : Investigating the AndraTec Guidewires,PTA Balloons and Stents in Iliac Disease.

Peripheral Artery Disease | Iliac Artery Disease
National Cancer Institute (NCI)

Active, not recruiting

Testing Crizotinib as a Potential Targeted Treatment in Cancers With ROS1 Genetic Changes (MATCH-Subprotocol G)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
Oncology Specialists, S.C.

Completed

Study Combining Imatinib Mesylate (Gleevec) With Sorafenib in Patients With Androgen-independent Prostate Cancer (AIPC)

Prostate Cancer

United States
RenJi Hospital

Completed

Lenvatinib Combined With Gefitinib in the Treatment of Lenvatinib-resistant Hepatocellular Carcinoma

Hepatocellular Carcinoma | Molecular Targeted Therapy

China
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)

Completed

Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer

Lung Cancer

United States
Marmara University

Not yet recruiting

Oral Motor Intervention to Preterms by Their Mothers

Premature

Turkey
National Cancer Institute (NCI)

Active, not recruiting

Testing Crizotinib as a Potential Targeted Treatment in Cancers With ALK Genetic Changes (MATCH-Subprotocol F)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
Sameek Roychowdhury

Active, not recruiting

Ponatinib for Patients Whose Advanced Solid Tumor Cancer Has Activating Mutations Involving the Following Genes: FGFR1, FGFR2, FGFR3, FGFR4, RET, KIT.

Malignant Neoplasm

United States
PrECOG, LLC.
Pfizer

Terminated

NEXT: Subsequent Exposure to Tyrosine Kinase Inhibition at Recurrence After Adjuvant Therapy in Renal Cell Carcinoma (PrE0801)

Renal Cell Carcinoma

United States
RenJi Hospital

Recruiting

Lenvatinib Plus VIC-1911 in Lenvatinib-unresponsive or Lenvatinib-resistant HCC

Hepatocellular Carcinoma | Liver Cancer | Resistant Cancer

China
National Cancer Institute (NCI)

Active, not recruiting

Ibrutinib in Treating Patients With Relapsed Hairy Cell Leukemia

Hairy Cell Leukemia | Recurrent Hairy Cell Leukemia | Hairy Cell Leukemia Variant

United States
H. Lee Moffitt Cancer Center and Research Institute
Novartis Pharmaceuticals

Active, not recruiting

Study of Trametinib + Ceritinib in Patients With Unresectable Melanoma

Melanoma | Unresectable Melanoma | Advanced Melanoma

United States
National Cancer Institute (NCI)

Recruiting

Study of Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis From Colorectal, Appendiceal, Small Bowel, Gastric, Cholangiocarcinoma, Breast, Ovarian, or Other Gynecologic Primary Cancer

Gynecologic Cancer | Colorectal Neoplasms | Colorectal Cancer | Ovarian Neoplasms | Peritoneal Neoplasms | Ovarian Cancer | Peritoneal Carcinomatosis | Appendiceal Neoplasms | Appendiceal Cancer | Gynecologic Neoplasms

United States
University Hospital, Toulouse

Completed

Oxytocin Intranasal Administrations in Children With Prader-Willi Syndrome Aged From 3 to 12 Years (Oxyjeune)

Prader-Willi Syndrome

France
National Cancer Institute (NCI)

Withdrawn

Wee1 Kinase Inhibitor AZD1775 and Combination Chemotherapy in Treating Children, Adolescents and Young Adults With Relapsed or Refractory Acute Myeloid Leukemia

Recurrent Adult Acute Myeloid Leukemia | Recurrent Childhood Acute Myeloid Leukemia | CNS 2a | CNS 2b | CNS 2c | CNS1
Sichuan Cancer Hospital and Research Institute

Recruiting

TACE, Sorafenib and PD-1 Monoclonal Antibody in the Treatment of HCC

Liver Diseases | Digestive System Neoplasms | Liver Neoplasms | Hepatocellular Carcinoma | Antineoplastic Agents | Molecular Mechanisms of Pharmacological Action | Protein Kinase Inhibitors | Sorafenib

China
Boehringer Ingelheim

Completed

A Study in Healthy Men to Find the Best Formulation for Once Daily Intake of Nintedanib

Healthy

United Kingdom
Tianjin Medical University Cancer Institute and...

Unknown

PD-1 Monoclonal Antibody, Lenvatinib and TACE in the Treatment of HCC (PLTHCC)

Hepatocellular Carcinoma Non-resectable

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Recruiting

Adebrelimab and a TKI in Combination With GEMOX in First-line Treatment of Advanced Biliary Tract Cancers (BTC)

Biliary Tract Cancer | Gemox Chemotherapy

China
LaNova Medicines Limited

Terminated

A Clinical Study Preliminary Efficacy of LM-061 Tablet in Subjects With Advanced Tumours

Advanced Tumours

China
NCIC Clinical Trials Group
Astex Pharmaceuticals, Inc.

Completed

Aurora Kinase Inhibitor AT9283 in Treating Patients With Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma

Unspecified Adult Solid Tumor, Protocol Specific | Non-Hodgkins Lymphoma

Canada
Cyclacel Pharmaceuticals, Inc.

Terminated

A Phase I Pharmacologic Study of CYC116, an Oral Aurora Kinase Inhibitor, in Patients With Advanced Solid Tumors

Solid Tumors

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Ibrutinib in Treating Participants With Untreated High Risk Smoldering Mantle Cell Lymphoma

Mantle Cell Lymphoma

United States
AstraZeneca
Daiichi Sankyo

Not yet recruiting

A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung15)

Metastatic Non-small Cell Lung Cancer
Shanghai JMT-Bio Inc.

Not yet recruiting

JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Exon 20ins Mutations

Local Advanced or Metastatic NSCLC
EMD Serono

Terminated

A Phase I, Dose-escalation Study of AS703569 Given Orally to Subjects With Haematological Malignancies

Haematological Malignancies

Italy, United States, Switzerland, Belgium, Germany
Cephalon

Completed

Open-Label Study to Determine the Maximum Tolerated Oral Dose of the Kinase Inhibitor CEP-11981 in Patients With Advanced Cancer

Cancer
Kamada, Ltd.

Completed

Phase II Study to Evaluate the Efficacy and Safety of Glassia® in Type-1 Diabetes

New Onset Type-1 Diabetes

Israel
Fred Hutchinson Cancer Center
AstraZeneca

Recruiting

Acalabrutinib for the Treatment of Chronic Graft Versus Host Disease

Hematopoietic and Lymphoid Cell Neoplasm | Recurrent Moderate-Severe Chronic Graft Versus Host Disease

United States
Chinese PLA General Hospital

Recruiting

The Safety and Efficacy of Thermal Ablation Combined With Apatinib and Carilimub for Advanced Liver Cancer

BCLC Stage B Hepatocellular Carcinoma | BCLC Stage C Hepatocellular Carcinoma

China
UNC Lineberger Comprehensive Cancer Center
AstraZeneca

Completed

Dose-escalating AZD1775 + Concurrent Radiation + Cisplatin for Intermediate/High Risk HNSCC

Carcinoma, Squamous Cell of Head and Neck

United States
AstraZeneca

Active, not recruiting

Safety, Tolerability and Pharmacokinetics of AZD1775 (Adavosertib) Plus MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumours

Advanced Solid Tumours

United States
Melanoma Institute Australia
Merck Sharp & Dohme LLC

Not yet recruiting

Neoadjuvant Pembrolizumab and Lenvatinib for Mucosal Melanoma (Neo PeLeMM)

Mucosal Melanoma

Australia
University of South Carolina

Completed

The Fasting and Shifted Timing (FAST) of Eating Study (FAST)

Overweight and Obesity

United States

Search clinical trials for: Wee-1 kinase inhibitor AZD1775

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Myanmar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations